ArticleAACE endocrinology and diabetes
Bilateral Basal Ganglia Calcifications in a 61-Year-Old Woman With Normocalcemic Hyperparathyroidism.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Bilateral basal ganglia calcifications are rare manifestations of neurodegenerative disorders associated with disturbances of brain calcium-phosphorus homeostasis. This report describes a patient with Fahr's syndrome secondary to normocalcemic primary hyperparathyroidism, a rarely reported entity that should be considered as a differential diagnosis. Case Report: A 61-year-old woman consulted the medical service stating: "I had a seizure and fell off my motorcycle." She reported experiencing syncope, vertigo, dizziness, dysarthria, limited lateral head movements, neck extension, and headache. These symptoms had been ongoing for a year. No significant medical history was identified, and no positive findings were noted on physical examination. Corrected serum calcium 9.83 mg/dL (8.6-10.3 mg/dL), parathyroid hormone 228.7 pg/mL (15-65 pg/mL), vitamin D 23 ng/mL (>20 ng/mL), thyroid-stimulating hormone 10.34 mU/L (0.4-4.5 mU/L), and free T4 0.81 ng/dL (0.8-1.9 ng/dL). A parathyroid ultrasound revealed 2 nodular images. Treatment with levetiracetam 500 mg every night was started. She currently experiences occasional episodes of vertigo and headache. Discussion: Fahr's syndrome is characterized by bilateral basal ganglia calcifications and has a multifactorial etiology. Differential diagnoses include infections and congenital disorders. In normocalcemic primary hyperparathyroidism, ectopic calcifications may arise from variations in serum calcium and reduced vitamin D production. Pharmacologic treatment focuses on managing neuropsychiatric symptoms, often involving anticonvulsants. Conclusion: Normocalcemic primary hyperparathyroidism is increasingly linked to Fahr's syndrome, highlighting the need to consider metabolic disorders despite normal calcium levels. Early diagnosis enhances targeted management, improving symptom control and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.